Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Company Performance - Gilead Sciences (GILD) shares have increased by 13.3% over the past month, reaching a new 52-week high of $106.69 [1] - Year-to-date, Gilead has gained 12.7%, outperforming the Zacks Medical sector's 4.4% and the Zacks Medical - Biomedical and Genetics industry's 12.6% [1] Earnings and Revenue Expectations - Gilead has consistently exceeded earnings consensus estimates, reporting EPS of$ 1.9 against a consensus of $1.67 in its last earnings report [2] - For the current fiscal year, Gilead is projected to achieve earnings of$ 7.80 per share on revenues of $28.41 billion, reflecting a 68.83% increase in EPS but a slight revenue decline of -1.18% [3] - The next fiscal year forecasts earnings of$ 8.12 per share on $29.58 billion in revenues, indicating year-over-year changes of 4.14% in EPS and 4.11% in revenues [3] Valuation Metrics - Gilead's current valuation metrics show a trading multiple of 13.3X current fiscal year EPS estimates, below the peer industry average of 22.6X [7] - The stock trades at 12X trailing cash flow compared to the peer group's average of 16X, with a PEG ratio of 0.89 [7] Zacks Rank and Style Scores - Gilead holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, indicating potential for further gains [8] - The company has a Value Score of A, Growth Score of B, and Momentum Score of D, resulting in a combined VGM Score of A [6] Industry Comparison - Gilead's performance is strong relative to its industry, with ANI Pharmaceuticals, Inc. (ANIP) also showing positive metrics, including a Zacks Rank of 2 (Buy) and a Value Score of A [9] - The Medical - Biomedical and Genetics industry is positioned in the top 28% of all industries, suggesting favorable conditions for both Gilead and ANIP [11]